4-(2-Amino-9H-purin-9-yl)-2-(hydroxymethyl)butyl acetate
CAS: 120687-07-2
Ref. 3D-VEA68707
| 25mg | Discontinued | ||
| 50mg | Discontinued | ||
| 100mg | Discontinued | ||
| 250mg | Discontinued | ||
| 500mg | Discontinued |
Product Information
- 2-[2-(2-Amino-9H-purin-9-yl)ethyl]-3-hydroxypropyl acetate
- 1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, monoacetate (ester)
- BRL 43594
- 1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, 1-acetate
- 2-(Hydroxymethyl)-4-(2-imino-1H-purin-9(2H)-yl)butyl acetate
Medoxomil is a prodrug of medroxyprogesterone acetate that is used to treat endometriosis and symptoms of premenstrual syndrome. Medoxyprogesterone acetate is converted to medroxyprogesterone, which inhibits the production of follicle-stimulating hormone (FSH) in the anterior pituitary gland. This inhibition of FSH causes a decrease in estradiol levels, which leads to a decrease in the symptoms associated with endometriosis and premenstrual syndrome. Medoxyprogesterone acetate also has been shown to have mediated activity on intestinal cells and liver cells, where it mediates the conversion of cilexetil to its active form. Medoxyprogesterone acetate has been found to be nonproductive in vitro, but can be quantified by incubating it with S9 from a rat's liver for four hours. The concentrations are then determined by measuring the amount of
